# GlycoMimetics Inc. (GLYC)

Source: https://www.quantisnow.com/company/GLYC
Generated: 2026-10-28T04:07:21.111Z

- Ticker: GLYC
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2014
- Website: glycomimetics.com

## About

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359 to target E-selectin and a chemokine receptors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.

## Latest GLYC news and filings

- 2025-06-30 20:21 UTC [SEC Form 3] [SEC Form 3 filed by new insider Im Ellie Eunkyung](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-im-ellie-eunkyung-6103812)
- 2025-06-30 20:16 UTC [SEC Form 3] [SEC Form 3 filed by new insider Bispham Barbara Harlin](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-bispham-barbara-harlin-6103764)
- 2025-06-23 22:51 UTC [SEC Form 4] [SEC Form 4 filed by Director Moran Susan](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-moran-susan-6096231)
- 2025-06-23 22:48 UTC [SEC Form 4] [SEC Form 4 filed by Director Fairmount Funds Management Llc](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-fairmount-funds-management-llc-6096224)
- 2025-06-23 22:46 UTC [SEC Form 4] [SEC Form 4 filed by Director Violin Jonathan](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-violin-jonathan-6096221)
- 2025-06-23 22:43 UTC [SEC Form 4] [SEC Form 4 filed by Director Balcom Alexandra](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-balcom-alexandra-6096220)
- 2025-06-23 22:41 UTC [SEC Form 4] [SEC Form 4 filed by Director Lubner David Charles](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-lubner-david-charles-6096214)
- 2025-06-23 22:29 UTC [SEC Form 3] [SEC Form 3 filed by new insider Lynch Ryan](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-lynch-ryan-6096182)
- 2025-06-23 22:29 UTC [SEC Form 3] [New insider Doughty Christopher Grant claimed ownership of 39,480 units of Ordinary Shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-doughty-christopher-grant-claimed-ownership-of-39480-units-6096180)
- 2025-06-23 22:28 UTC [SEC Form 3] [SEC Form 3 filed by new insider Scalzo Richard William](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-scalzo-richard-william-6096178)
- 2025-06-23 22:27 UTC [SEC Form 3] [New insider Mcneill Jonathan claimed ownership of 134,200 units of Ordinary Shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-mcneill-jonathan-claimed-ownership-of-134200-units-of-6096176)
- 2025-06-23 22:26 UTC [SEC Form 3] [New insider Brumm Joshua T claimed ownership of 268,400 units of Ordinary Shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-brumm-joshua-t-claimed-ownership-of-268400-units-6096175)
- 2025-06-23 22:25 UTC [SEC Form 3] [New insider Fairmount Funds Management Llc claimed ownership of 1,387,866 units of Ordinary Shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-fairmount-funds-management-llc-claimed-ownership-of-1387866-6096174)
- 2025-06-23 22:24 UTC [SEC Form 3] [SEC Form 3 filed by new insider Lubner David Charles](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-lubner-david-charles-6096171)
- 2025-06-23 22:23 UTC [SEC Form 3] [New insider Violin Jonathan claimed ownership of 69,515 units of Ordinary Shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-violin-jonathan-claimed-ownership-of-69515-units-of-6096170)
- 2025-06-23 22:23 UTC [SEC Form 3] [SEC Form 3 filed by new insider Balcom Alexandra](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-balcom-alexandra-6096169)
- 2025-06-23 22:22 UTC [SEC Form 3] [SEC Form 3 filed by new insider Moran Susan](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-moran-susan-6096168)
- 2025-06-18 21:28 UTC [SEC Form 8-K] [GlycoMimetics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Leadership Update, Financial Statements and Exhibits, Results of Operations and Financial Condition, Material Modification to Rights of Security Holders, Changes in Registrant's Certifying Accountant, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Change in Shell Company Status, Regulation FD Disclosure](https://www.quantisnow.com/insight/glycomimetics-inc-filed-sec-form-8-k-entry-into-a-material-6092388)
- 2025-06-17 22:53 UTC [SEC Form 4] [Large owner Bvf Partners L P/Il acquired 1,270,004 shares (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-bvf-partners-l-pil-acquired-1270004-shares-sec-6090714)
- 2025-06-06 12:30 UTC [SEC Form 8-K] [GlycoMimetics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/glycomimetics-inc-filed-sec-form-8-k-regulation-fd-disclosure-other-6075653)
- 2025-06-05 20:01 UTC [GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals](https://www.quantisnow.com/insight/glycomimetics-stockholders-approve-proposed-merger-with-crescent-biopharma-and-all-6074244)
- 2025-05-30 12:30 UTC [SEC Form 425] [SEC Form 425 filed by GlycoMimetics Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-glycomimetics-inc-6064416)
- 2025-05-30 12:30 UTC [SEC Form 8-K] [GlycoMimetics Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/glycomimetics-inc-filed-sec-form-8-k-other-events-6064411)
- 2025-05-29 12:30 UTC [SEC Form 425] [SEC Form 425 filed by GlycoMimetics Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-glycomimetics-inc-6062528)
- 2025-05-29 11:30 UTC [Conference Announcement] [Crescent Biopharma to Present at the Jefferies Global Healthcare Conference](https://www.quantisnow.com/insight/crescent-biopharma-to-present-at-the-jefferies-global-healthcare-conference-6062316)
- 2025-05-15 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by GlycoMimetics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-glycomimetics-inc-6040443)
- 2025-05-14 21:06 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by GlycoMimetics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-glycomimetics-inc-6039833)
- 2025-05-14 20:39 UTC [SEC Form 424B3] [SEC Form 424B3 filed by GlycoMimetics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-glycomimetics-inc-6039563)
- 2025-05-12 11:12 UTC [SEC Form S-4] [Amendment: SEC Form S-4/A filed by GlycoMimetics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-4a-filed-by-glycomimetics-inc-6031663)
- 2025-04-29 00:17 UTC [SEC Form S-4] [Amendment: SEC Form S-4/A filed by GlycoMimetics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-4a-filed-by-glycomimetics-inc-6005715)
- 2025-04-29 00:01 UTC [SEC Form 425] [SEC Form 425 filed by GlycoMimetics Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-glycomimetics-inc-6005708)
- 2025-04-29 00:00 UTC [SEC Form 8-K] [GlycoMimetics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits](https://www.quantisnow.com/insight/glycomimetics-inc-filed-sec-form-8-k-entry-into-a-material-6005703)
- 2025-04-28 12:00 UTC [SEC Form 425] [SEC Form 425 filed by GlycoMimetics Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-glycomimetics-inc-6003836)
- 2025-04-28 11:30 UTC [Leadership Update] [Crescent Biopharma Appoints David Lubner to Board of Directors](https://www.quantisnow.com/insight/crescent-biopharma-appoints-david-lubner-to-board-of-directors-6003713)
- 2025-04-04 17:29 UTC [SEC Form S-4] [Amendment: SEC Form S-4/A filed by GlycoMimetics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-s-4a-filed-by-glycomimetics-inc-5977643)
- 2025-04-03 11:30 UTC [SEC Form 425] [SEC Form 425 filed by GlycoMimetics Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-glycomimetics-inc-5974387)
- 2025-04-03 11:30 UTC [SEC Form 425] [SEC Form 425 filed by GlycoMimetics Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-glycomimetics-inc-5974385)
- 2025-04-03 11:30 UTC [Public Offering] [Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics](https://www.quantisnow.com/insight/crescent-biopharma-appoints-joshua-brumm-as-chief-executive-officer-and-5974383)
- 2025-03-21 12:14 UTC [Analyst Coverage Initiated] [Cantor Fitzgerald initiated coverage on GlycoMimetics](https://www.quantisnow.com/insight/cantor-fitzgerald-initiated-coverage-on-glycomimetics-5955428)
- 2025-02-28 22:05 UTC [SEC Form 425] [SEC Form 425 filed by GlycoMimetics Inc.](https://www.quantisnow.com/insight/sec-form-425-filed-by-glycomimetics-inc-5918049)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/GLYC
- RSS and alerts for GLYC: https://www.quantisnow.com/docs/rss-feeds.md